Mark A. Velleca
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Mark A. Velleca
Mark A. Velleca is recorded as CEO at Black Diamond Therapeutics, Inc. (BDTX). Black Diamond Therapeutics, Inc. reported in an 8-K filed September 18, 2023 that Mark A. Velleca was appointed President and Chief Executive Officer and principal executive officer, effective September 16, 2023. The proxy statement of Black Diamond Therapeutics, Inc. reports total compensation of $2,234,919 for Mark A. Velleca in fiscal 2025, including a base salary of $667,400. Disclosed compensation is on record for 3 fiscal years.
“Effective September 16, 2023, the Board appointed Mark A. Velleca, M.D., Ph.D. as President and Chief Executive Officer and principal executive officer of the Company (the "Appointment").”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2023-09-16–present
-
2021-01-01–2024-04-24
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Black Diamond Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Mark A. Velleca, M.D., Ph.D. CEO, Chairman
- Mark Velleca CEO
- Mark Velleca, M.D., Ph.D. CEO, Board Member
- Erika Jones CFO, Chief Accounting Officer, Board Member
- Brent Hatzis-Schoch Board Member
- Elizabeth Buck Board Member
- Kapil Dhingra Board Member
- Melanie Morrison Board Member
- Prakash Raman, Ph.D. Board Member
- Robert A. Ingram Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Black Diamond Therapeutics, Inc. (BDTX) | M.D., Ph.D. President and Chief Executive Officer | $667,400 | $2,234,919 |
| 2024 | Black Diamond Therapeutics, Inc. (BDTX) | M.D., Ph.D. President and Chief Executive Officer | $644,800 | $2,855,111 |
| 2023 | Black Diamond Therapeutics, Inc. (BDTX) | M.D., Ph.D. President and Chief Executive Officer | $180,833 | $2,949,854 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.